HC Wainwright Comments on Xeris Biopharma Q1 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Xeris Biopharma in a research report issued on Friday, March 7th. HC Wainwright analyst O. Livnat anticipates that the company will post earnings per share of ($0.08) for the quarter. HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for Xeris Biopharma's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Xeris Biopharma's Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at $0.01 EPS and FY2029 earnings at $0.78 EPS.

A number of other equities analysts have also issued reports on the company. Jefferies Financial Group reaffirmed a "buy" rating and set a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Craig Hallum increased their price target on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research report on Friday, March 7th. Leerink Partners raised their price target on Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a research note on Friday, March 7th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $5.92.

Remove Ads

Xeris Biopharma Trading Up 0.5 %

XERS traded up $0.03 on Monday, hitting $4.60. 2,117,066 shares of the company's stock were exchanged, compared to its average volume of 2,118,287. The firm has a market cap of $685.03 million, a PE ratio of -10.21 and a beta of 2.32. Xeris Biopharma has a twelve month low of $1.69 and a twelve month high of $4.68. The stock has a fifty day moving average of $3.64 and a two-hundred day moving average of $3.29.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. NewEdge Advisors LLC bought a new position in shares of Xeris Biopharma in the fourth quarter valued at $34,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Xeris Biopharma during the 3rd quarter worth $35,000. R Squared Ltd bought a new position in Xeris Biopharma in the 4th quarter valued at about $42,000. Quantbot Technologies LP acquired a new position in Xeris Biopharma during the third quarter valued at approximately $44,000. Finally, Cibc World Markets Corp bought a new position in Xeris Biopharma in the fourth quarter valued at about $44,000. Institutional investors and hedge funds own 42.75% of the company's stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.